Publication 論文一覧

  • 112.

    Tachibana M, Takashima E, Torii M, Wu Y, Sattabongkot J, Tsuboi T.
    Advances in transmission-blocking vaccines against Plasmodium falciparum and Plasmodium vivax.
    Expert Rev Vaccines. 2025 Dec;24(1):509-523. doi: 10.1080/14760584.2025.2517720. Epub 2025 Jun 18.
    PMID: 40488614

  • 111.

    Yuguchi T, Dankyi BO, Rojrung R, Nagaoka H, Kanoi BN, Tiono AB, Nebie I, Ouedraogo A, Miura K, Sattabongkot J, Sirima SB, Tsuboi T, Takashima E.
    Antibody responses in Burkinabe children against P. falciparum proteins associated with reduced risk of clinical malaria.
    Front Immunol. 2025 Feb 26;16:1521082. doi: 10.3389/fimmu.2025.1521082. eCollection 2025.
    PMID: 40079008

  • 110.

    Fukumoto J, Tsuboi T, Takashima E.
    Ultrastructural expansion microscopy (U-ExM) visualization of malaria parasite dense granules using RESA as a representative marker protein.
    Parasitol Int. 2025 Jun;106:103023. doi: 10.1016/j.parint.2024.103023. Epub 2024 Dec 26.
    PMID: 39732432

  • 109.

    Takashima E, Tsuboi T.
    RH5: rationally-designed malaria vaccine antigen improving efficacy.
    Trends Parasitol. 2024 Oct;40(10):870-872. doi: 10.1016/j.pt.2024.09.001. Epub 2024 Sep 13.
    PMID: 39277508

  • 108.

    Walker IS, Dini S, Aitken EH, Damelang T, Hasang W, Alemu A, Jensen ATR, Rambhatla JS, Opi DH, Duffy MF, Takashima E, Harawa V, Tsuboi T, Simpson JA, Mandala W, Taylor TE, Seydel KB, Chung AW, Rogerson SJ.
    A systems serology approach to identifying key antibody correlates of protection from cerebral malaria in Malawian children.
    BMC Med. 2024 Sep 12;22(1):388. doi: 10.1186/s12916-024-03604-8.
    PMID: 39267089

  • 107.

    Yamada H, Osaka H, Tatsumi N, Araki M, Abe T, Kaihara K, Takahashi K, Takashima E, Uchihashi T, Naruse K, Takei K.
    Direct Binding of Synaptopodin 2-Like Protein to Alpha-Actinin Contributes to Actin Bundle Formation in Cardiomyocytes.
    Cells. 2024 Aug 17;13(16):1373. doi: 10.3390/cells13161373.
    PMID: 39195263

  • 106.

    Hagadorn KA, Peterson ME, Kole H, Scott B, Skinner J, Diouf A, Takashima E, Ongoiba A, Doumbo S, Doumtabe D, Li S, Sekar P, Yan M, Zhu C, Nagaoka H, Kanoi BN, Li QZ, Long C, Long EO, Kayentao K, Jenks SA, Sanz I, Tsuboi T, Traore B, Bolland S, Miura K, Crompton PD, Hopp CS.
    Autoantibodies inhibit Plasmodium falciparum growth and are associated with protection from clinical malaria.
    Immunity. 2024 Aug 13;57(8):1769-1779.e4. doi: 10.1016/j.immuni.2024.05.024. Epub 2024 Jun 19.
    PMID: 38901428

  • 105.

    Takashima E, Otsuki H, Morita M, Ito D, Nagaoka H, Yuguchi T, Hassan I, Tsuboi T.
    The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates for Plasmodium falciparum.
    Biomolecules. 2024 Jan 12;14(1):100. doi: 10.3390/biom14010100.
    PMID: 38254700

  • 104.

    Kunkeaw N, Nguitragool W, Takashima E, Kangwanrangsan N, Muramatsu H, Tachibana M, Ishino T, Lin PJC, Tam YK, Pichyangkul S, Tsuboi T, Pardi N, Sattabongkot J.
    A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax.
    NPJ Vaccines. 2023 Dec 14;8(1):187. doi: 10.1038/s41541-023-00786-9.
    PMID: 38092803

  • 103.

    Inklaar MR, de Jong RM, Bekkering ET, Nagaoka H, Fennemann FL, Teelen K, van de Vegte-Bolmer M, van Gemert GJ, Stoter R, King CR, Proellochs NI, Bousema T, Takashima E, Tsuboi T, Jore MM.
    Pfs230 Domain 7 is targeted by a potent malaria transmission-blocking monoclonal antibody.
    NPJ Vaccines. 2023 Dec 12;8(1):186. doi: 10.1038/s41541-023-00784-x.
    PMID: 38086855